Osteoporosis: What You Had, What You Lost, and What You Gain

OR01-1

Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of the Phase 3 Open-Label Structure Study
B Langdahl, C Libanati, D B Crittenden, M A Bolognese, J P Brown, N S Daizadeh, E Dokoupilova, K Engelke, J S Finkelstein, H K Genant, S Goemaere, L Hyldstrup, E Jodar-Gimeno, T M Keaveny, David L Kendler, P Lakatos, J Maddox, J Malouf, F Massari, J F Molina, M R Ulla and A Grauer

OR01-2

Abaloparatide Significantly Reduces Vertebral and Nonvertebral Fractures and Increases BMD Regardless of Baseline Risk
Felicia Cosman, Gary Hattersley, Paul D Miller, Ming-yi Hu, Luis Augusto Russo, Bente Juel Riis, Gregory C Williams and Lorraine A Fitzpatrick

OR01-3

Anti-Mullerian Hormone and Prediction of Trans-Menopausal Bone Loss
Arun S Karlamangla, Albert Shieh, Sherri-Ann M Burnett-Bowie, Elaine W. Yu, Gail A Greendale, Patrick M. Sluss, Deborah Martin and Joel S Finkelstein

OR01-4

Low Plasma Leucine-Rich Repeat-Containing 17 (LRRc17) Level Is an Independent and Additive Risk Factor for Prevalent Vertebral Fractures in Postmenopausal Women
Namki Hong, Beom-Jun Kim, Chong Hwa Kim, Ki-Hyun Baek, Yong-Ki Min, Deog-Yoon Kim, Seung Hun Lee, Jung-Min Koh, Moo-Il Kang and Yumie Rhee

OR01-5

Use of Stimulant Medications and Bone Mass in Children and Adolescents: An Nhanes Study
Alexis Jamie Feuer, Ashley Thai, Ryan T Demmer and Maria G Vogiatzi

OR01-6

Delay in Oestrogen Commencement Is Associated with Lower Spine and Hip Bone Mineral Density in Turner Syndrome
Hanh Nguyen, Phillip Wong, Boyd J Strauss, Peter R Ebeling, Frances Milat and Amanda Vincent